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Stable Foxp3 expression is required for the develop-
ment of functional regulatory T (Treg) cells. Here, we
demonstrate that the expression of the transcription
factor Foxp3 can be regulated through the poly-
ubiquitination of multiple lysine residues, resulting
in proteasome-mediated degradation. Expression
of the deubiquitinase (DUB) USP7 was found to be
upregulated and active in Treg cells, being associ-
ated with Foxp3 in the nucleus. Ectopic expression
of USP7 decreased Foxp3 polyubiquitination and
increased Foxp3 expression. Conversely, either
treatment with DUB inhibitor or USP7 knockdown
decreased endogenous Foxp3 protein expression
and decreased Treg-cell-mediated suppression
in vitro. Furthermore, in a murine adoptive-transfer-
induced colitis model, either inhibition of DUB activ-
ity or USP7 knockdown in Treg cells abrogated their
ability to resolve inflammation in vivo. Our data reveal
a molecular mechanism in which rapid temporal
control of Foxp3 expression in Treg cells can be
regulated by USP7, thereby modulating Treg cell
numbers and function.
INTRODUCTION
Foxp3+ regulatory T (Treg) cells are a specific subset of CD4+
T cells that are crucial for the maintenance of self-tolerance
(Khattri et al., 2003; Fontenot et al., 2003). The X-chromo-some-encoded transcription factor Foxp3 is essential for both
Treg cell development and function. Foxp3 mutations in mice
as well as in immune dysregulation polyendocrinopathy, enter-
opathy, and X-chromosome-linked syndrome (IPEX) patients
result in the development of complex autoimmune diseases
due to Treg cell deficiency (Khattri et al., 2003). T cells manipu-
lated to ectopically express Foxp3 acquire the Treg cell pheno-
type (Khattri et al., 2003; Hori et al., 2003). Furthermore, a 90%
decrease of Foxp3 protein expression due to destabilizing alter-
ations in the 30 UTR of the Foxp3 messenger RNA (mRNA),
thereby destabilizing mRNA, results in significantly impaired
Treg-cell-mediated suppression, demonstrating that the amount
of Foxp3 protein directly correlates to Treg cell function (Wan
and Flavell, 2007).
Constitutive expression of Foxp3 has been demonstrated to
be essential for themaintenance of Treg cell suppressor function
(Williams and Rudensky, 2007). Although the precise molecular
mechanisms regulating expression of the Foxp3 gene are incom-
pletely understood, it has been reported that TGF-b, IL-2, or
T cell receptor (TCR) stimulation of T cells can all result in
increased Foxp3 expression (Kim and Leonard, 2007; Yao
et al., 2007). This is most likely modulated by the demethylation
of the Foxp3 promoter or conserved noncoding regions in the
Foxp3 locus (Kim and Leonard, 2007). In addition, multiple
transcription factors, including CREB-ATF, Ets-1, Foxo1 and
Foxo3, and STAT5 have been demonstrated to regulate Foxp3
transcription (Ouyang et al., 2010; Polansky et al., 2010; Yao
et al., 2007; Kim and Leonard, 2007).
Foxp3 expression in Treg cell is not unique, given that in vitro
TCR stimulation of CD4+CD25 T cells results in the transient
expression of Foxp3 mRNA and protein. However, the vast
majority of cells do not exhibit a suppressive phenotype, and it
is possible that Foxp3 acts here to prevent T cell hyperactivationImmunity 39, 259–271, August 22, 2013 ª2013 Elsevier Inc. 259
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subpopulation of these TCR-stimulated CD4+CD25 cells ex-
presses both high and stable Foxp3 protein, thus acquiring sup-
pressive capacity (Allan et al., 2005; Passerini et al., 2008). These
studies, as well as others, have shown that the persistent
expression of Foxp3 is essential for themaintenance of suppres-
sor function.
Currently, there is debate as to whether Foxp3+ Treg cells can
lose Foxp3 expression and suppressive function and whether
they exhibit characteristics of other Th cell subsets. Several
independent studies in which Foxp3+ Treg cells were adoptively
transferred into lymphopenicmice demonstrated that 10%–50%
of the transferred cells lost Foxp3 expression (Gavin et al., 2007;
Komatsu et al., 2009; Duarte et al., 2009). Furthermore, Treg cells
from both the periphery and the thymus were found to be con-
verted into Th17 cells upon stimulation with anti-CD3, anti-
CD28, and IL-6, demonstrating a degree of plasticity (Yang
et al., 2008). In addition, Foxp3+ Treg cells have been shown to
convert to a Foxp3 Th1 cell phenotype upon Toxoplasma infec-
tion (Oldenhove et al., 2009). In contrast, studies with (condi-
tional) Foxp3 GFP-CRE mice that were crossed with ROSA26
reporter mice demonstrated that Foxp3 was remarkably stable
and that only a very small subpopulation lost its Foxp3 expres-
sion (Rubtsov et al., 2010; Miyao et al., 2012). These differences
could potentially be explained by the ‘‘pollution’’ of Teff cells that
transiently upregulate Foxp3 without gaining a Treg cell pheno-
type. In addition, Miyao et al. (2012) demonstrated that Foxp3+
Treg cells could transiently downregulate Foxp3 expression,
which was rapidly regained along with suppressive capacity
upon activation. Because these studies have all demonstrated
that Foxp3 protein expression can be rapidly and, often, tran-
siently lost, we have focused on the molecular mechanism
regulating this process.
Protein expression in cells can be regulated by both protein
production and degradation rates. Much of the regulated prote-
olysis in eukaryotic cells is catalyzed by the ubiquitin-protea-
some system (Ciechanover and Schwartz, 2002). Covalently
attached ubiquitin chains of four or more ubiquitin proteins
mark a protein for degradation by the 26S proteasome (Hoch-
strasser, 2006). Protein ubiquitination is a tightly regulated pro-
cess modulated by E1, E2, and E3 ligases, which, in a complex,
catalyze the addition of ubiquitin to lysine residues of the target
protein. Here, the initial ubiquitin serves as an acceptor for addi-
tional cycles of ubiquitin modification, resulting in a developing
polyubiquitin chain (Eldridge and O’Brien, 2010). Protein deubi-
quitination is an equally well-regulated process modulated by a
large family of deubiquitinating enzymes (DUBs). DUBs catalyze
the removal of ubiquitin from specific protein substrates, thereby
preventing protein degradation, resulting in increased target
protein expression (Nijman et al., 2005).
Our group, as well as others, has previously shown that Foxp3
can be polyubiquitinated; however, the regulation of this process
and its modulators has remained elusive (Dang et al., 2011; van
Loosdregt et al., 2011; van Loosdregt et al., 2010). Here, we
establish that the DUB USP7 (also known as HAUSP) is active
in primary Treg cells and associates with Foxp3. Ectopic expres-
sion of USP7 specifically decreased Foxp3 polyubiquitination,
resulting in increased Foxp3 protein expression. Conversely,
knockdown of USP7 resulted in decreased Foxp3 protein.260 Immunity 39, 259–271, August 22, 2013 ª2013 Elsevier Inc.Furthermore, Treg cell function was noticeably decreased
when USP7 was knocked down or when DUB activity was
inhibited both in vitro and in vivo. The manipulation of Foxp3
ubiquitination provides a molecular mechanism for assuring
rapid temporal control of Foxp3 expression in T cells, thereby
regulating Treg cell numbers and function.
RESULTS
DUBs Modulate Treg-Cell-Mediated Suppression
To assess whether ubiquitination could regulate Treg-cell-medi-
ated suppression, we used a pan-DUB inhibitor (DUBi; Fig-
ure S1A available online) (Colombo et al., 2010; Patent WO,
2007). Carboxyfluorescein succinimidyl ester (CFSE)-labeled
peripheral blood mononuclear cells (PBMCs) were cocultured
with sorted human CD4+CD25highCD127low Treg cells that had
been pretreated with DUBi separately as described in the
Experimental Procedures. Treg-cell-mediated suppression was
significantly decreased by preincubating Treg cells with DUBi
(Figure 1A). Accordingly, IL-2 mRNA expression was upregu-
lated in Treg cells transiently treated with DUBi both 2 and
7 days after treatment (Figure S1B). Furthermore, treatment
with DUBi resulted in the decreased expression of additional
Foxp3 transcriptional target genes CD25 and GITR on Foxp3+
Treg cells (Figure S1C).
To determine whether ubiquitination could also modulate
Treg-cell-mediated suppression in vivo, we used a well-estab-
lished mouse adoptive transfer colitis model. Here, immunodefi-
cient mice are infused with CD4+CD45RBhigh T cells in order to
induce colitis, and disease severity could be reduced by the
adoptive transfer of Treg cells (Powrie et al., 1994). Initially,
sorted Treg cells isolated from Foxp3-GFPmice were pretreated
with DUBi and transferred into Rag1/ mice 3 weeks after the
infusion of naı¨ve CD4+ T cells. Mice were sacrificed 3 weeks after
Treg cell infusion, and colitis severity was assessed. Treatment
with Treg cells noticeably reduced disease scores in comparison
to mice that did not receive Treg cells (Figures 1B and 1C). Dis-
ease scores of mice receiving Treg cells pretreated with DUBi
were significantly increased in comparison to control mice, indi-
cating that the inhibition of DUB activity can significantly abro-
gate Treg-cell-mediated suppression in vivo. The percentage
of GFP+ cells in the spleen was similar in the experimental
groups, indicating that Treg cell survival was not affected (Fig-
ure 1D). Interestingly, Foxp3 protein expression was significantly
reduced in DUBi-treated Treg cells in comparison to untreated
Treg cells (Figures 1E and S1D). Given that (poly)ubiquitination
is a well-described modulator of protein degradation, these
data suggest that Foxp3 protein, and, thus, Treg cell function,
may be regulated by ubiquitination.
Foxp3 Protein Expression Is Regulated by
Polyubiquitination
First, to determine whether DUBs can regulate Foxp3 expres-
sion, we evaluated Foxp3 protein stability under normal culture
conditions. Foxp3-transfected cells or Treg cells were treated
with the protein translation inhibitor cycloheximide (CHX), and
Foxp3 protein expression was determined. In both transfected
human embryonic kidney (HEK) 293T cells (Figure 2A) and
human Treg cells (Figure 2B), the inhibition of translation led to
Figure 1. Ubiquitination Modulates Treg
Cell Function
(A) Sorted human CD4+CD25highCD127low Treg
cells were pretreated with 10 mM DUBi for 1 hr,
washed, and cocultured with CFSE-labeled
PBMCs in anti-CD3-coated wells for 4 days. CFSE
dilution of CD4+ cells was analyzed by flow
cytometry.
(B) CD4+CD45RBhigh cells were injected into
immunodeficient mice. Sorted GFP+ Treg cells
from Foxp3-GFP promoter mice were pre-
incubated with 10 mM DUBi for 1 hr and injected
3 weeks later. Mice were sacrificed 3 weeks after
Treg cell administration. Sections of the colon
were analyzed and scored (five mice per group).
(C) Representative hematoxylin- and eosin-
stained tissue slides of the colon.
(D) Analysis of CD4+GFP+ cell numbers in the
spleen.
(E) Percentage of Foxp3+ CD4+ T cells in the
spleen. Data shown are representative of at least
three independent experiments, *p<0.05.
Data are represented as mean + SEM. See also
Figure S1.
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Figure 2. Rapid Turnover of the Foxp3
Protein Is Mediated by Polyubiquitination
(A) HA-Foxp3-transfected HEK 293T cells were
treated with 150 mg/ml cycloheximide (CHX) for 0,
4, and 8 hr. Cell lysates were blotted and analyzed
with specific antibodies. Quantification of Foxp3
intensity relative to HSP90 is included.
(B) Human Treg cells were cultured in the pres-
ence of 150 mg/ml CHX as indicated. Foxp3
amounts were determined by western blot.
Quantification of Foxp3 intensity relative to tubulin
is included.
(C) Human Treg cells were cultured in the pres-
ence of 150 mg/ml CHX. Foxp3 amounts were
determined by flow cytometry.
(D) Ubiquitin pull-down for HA-Foxp3 or HA-Foxp3
K22xR as described in the Experimental Pro-
cedures.
(E) Human Treg cells were cultured with 20 mM
MG132 for 3 hr, cells were lysed, and ubiquitinated
proteins were isolated with TUBE-coupled beads.
Ubiquitinated Foxp3 was visualized by western
blot with anti-Foxp3.
(F and G) HA-Foxp3-transfected HEK 293T cells
(F) or Treg cells (G) were cultured with 5 mM DUBi
for 8 hr. Western blots were incubated with anti-
bodies against, HA, Foxp3, or tubulin, as indi-
cated. Data shown are representative of at least
three independent experiments. IP, immunopre-
cipitation; WB, western blot.
See also Figure S2.
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Foxp3 protein degradation. Importantly, Foxp3 mRNA expres-
sion in Treg cells was unchanged (Figure S2A). Similar results
were obtained when Foxp3 expression was analyzed in human
Treg cells by flow cytometry (Figure 2C). Accordingly, protein
expression of IL-2Ra (CD25), a direct Foxp3 transcriptional
target, also decreased upon CHX treatment (Figure S2B). To
further validate that Foxp3 is degraded, we treated Foxp3-trans-
fected HEK 293T cells or natural Treg (nTreg) cells with both CHX
and proteasome inhibitor MG132. MG132 treatment impaired
the effect of CHX, demonstrating that Foxp3 is indeed degraded
by the proteasome (Figures S2C and S2D).
Because we had observed that ubiquitination could modulate
Treg cell function, we subsequently analyzed the ubiquitination
status of Foxp3. HEK 293T cells transfected with both His-
tagged ubiquitin and hemagglutinin (HA)-tagged Foxp3 were
lysed, and ubiquitinated proteins were isolated with Ni-NTA
beads. Foxp3-specific polyubiquitination was determined by
immunoblot analysis with anti-HA. A clear polyubiquitination
pattern was observed with wild-type (WT) Foxp3 (Figure 2D),
and this was abrogated in a Foxp3 mutant in which all lysine
residues were mutated (Foxp3 K22xR), indicating that Foxp3 is262 Immunity 39, 259–271, August 22, 2013 ª2013 Elsevier Inc.directly ubiquitinated. Short-term treat-
ment with DUBi increased Foxp3 poly-
ubiquitination, suggesting a continuous
deubiquitination of Foxp3 (Figure 2D).
Although technically challenging, to con-
firm that Foxp3 can also be polyubiquiti-
nated in human Treg cells, we lysed cellsand incubated them with tandem ubiquitin-binding entities
(TUBE)-coupled agarose beads in order to isolate ubiquitinated
proteins. Again, Foxp3-specific polyubiquitination was visual-
ized by immunoblot analysis with anti-Foxp3. In the presence
of MG132, a clear polyubiquitin pattern was observed, demon-
strating that Foxp3 is polyubiquitinated in human Treg cells as
well (Figure 2E).
To determine whether Foxp3 polyubiquitination resulted in the
regulation of Foxp3 protein expression, we treated HA-Foxp3-
transfected cells (Figure 2F) or Treg cells (Figures 2G and S2E)
with DUBi, and Foxp3 protein expression was analyzed. Treat-
ment with DUBi decreased Foxp3 protein expression in both
cell types. Importantly, DUBi treatment did not affect Foxp3
mRNA expression in Treg cells (Figure S2F). Furthermore, the
effect of DUBi on Foxp3 protein expression was dose dependent
(Figure S2G). Given that b-catenin protein is heavily dependent
on polyubiquitination-mediated degradation, it was used as a
positive control for DUBi treatment. As expected, b-catenin
amounts were reduced upon treatment (Figure S2H). Foxp3
K22xR expression was not reduced by DUBi treatment because
this mutant cannot be polyubiquitinated (Figure S2I). To validate
that Foxp3 amounts were decreased because of increased
Figure 3. Identification of Multiple
Foxp3 Ubiquitination Sites
(A) Immunoprecipitated HA-Foxp3 was analyzed
for ubiquitinated lysine residues by MS. Peptides
continuing ubiquitinated lysine residues are de-
picted. Ubiquitinated lysine residues are underlined.
(B) A schematic representation of Foxp3 and the
lysine residues that are ubiquitinated. ZF, zinc finger
motive; LZ, leucine zipper motive; DBD, DNA-binding
motive.
(C) Ubiquitin pull-down for HA-Foxp3 or Foxp3 mu-
tants as described in the Experimental Procedures.
(D) FLAG-ubiquitin-Foxp3 or FLAG-ubiquitin-K7xR-
Foxp3 fusion constructs (in which all seven lysine
residues in ubiquitin are mutated to arginine) were
analyzed for ubiquitination as in (C). Data shown are
representative of at least three independent experi-
ments. WB, western blot.
See also Figure S3.
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ence of MG132. As expected, treatment with MG132 alone
increased Foxp3 expression (Figure S2J), whereas treatment
with DUBi resulted in reduced Foxp3 amounts. However, in the
presence of MG132, Foxp3 expression was unchanged after
DUBi treatment, demonstrating that Foxp3 protein degradation
is directly modulated by DUBs. Furthermore, Treg cells were
treated with DUBi in the presence of CHX. Again, either DUBi
or CHX treatment alone reduced Foxp3 protein expression (Fig-
ure S2K). Treatment with both compounds resulted in an even
greater reduction in Foxp3 amounts, yet again supporting a
role for DUBs in modulating Foxp3 degradation in Treg cells.
To determine whether the effect observed of treatment with
DUBi was long lasting, we treated Treg cells with DUBi for 1 hr,
and Foxp3 protein expression was evaluated either 1 or 7 days
after treatment. A single treatment for 1 hr resulted in reduced
Foxp3 expression 7 days after treatment (Figure S2L). Taken
together, these data show that Foxp3 protein degradation,
but not synthesis, is regulated posttranscriptionally, a process
that is polyubiquitination dependent and can be rescued by
deubiquitination.
Identification of Multiple Foxp3 Ubiquitination Sites
Because we could demonstrate that Foxp3 polyubiquitination
results in protein degradation, we examined whether specificImmunity 39, 259–2lysine residues could be ubiquitinated.
Using a mass spectrometry (MS) approach,
we found five distinct lysine residues in
Foxp3 to be ubiquitinated (K249, K251,
K263, K267, and K393; Figures 3A and
3B). Foxp3 expression constructs in which
all lysines were mutated into arginines
were generated (Foxp3 K22xR) or modified
to express combinations of the lysines iden-
tified. Subsequently, Foxp3 mutants were
analyzed for ubiquitination as previously
described. The addition of all five lysine res-
idues that were identified by MS rescued
Foxp3 ubiquitination. Similarly, the additionof only lysines 263 and 267 or 249, 251, and 393 restored Foxp3
ubiquitination to amounts similar to WT Foxp3 (Figure 3C).
To evaluate whether the specific location of modification
influences polyubiquitination, we generated a Foxp3 mutant in
which ubiquitin was directly fused to the N terminus. The Ubi-
Foxp3 fusion protein was highly polyubiquitinated and rapidly
degraded, suggesting that polyubiquitination is not dependent
on the specific location of lysine residues (Figure 3D). To further
verify that the ubiquitin fusion protein was indeed polyubiquiti-
nated, we generated a Ubi-K7xR-Foxp3 fusion construct in
which all lysines in ubiquitin, but not in Foxp3, were replaced
with arginines. Mutating the ubiquitin fusion protein reduced
Foxp3 polyubiquitination back to WT levels. Taken together,
these data show that Foxp3 can be polyubiquitinated at multiple
lysine residues, which most likely results in rapid proteasome-
mediated degradation.
USP7 Associates with and Deubiquitinates Foxp3
Next, we sought to determine which DUBs could potentially deu-
biquitinate Foxp3. First, we evaluated which DUBs were both
expressed and active in human Treg cells using an HA-tagged
probe that covalently binds active DUBs, thus allowing isolation
and identification (Borodovsky et al., 2002). Cell lysates from
both nTreg and induced Treg (iTreg) cells were incubated with
the DUB probe, and active DUBs were immunoprecipitated71, August 22, 2013 ª2013 Elsevier Inc. 263
Figure 4. USP7 Deubiquitinates Foxp3
(A) Human iTreg and nTreg cells were lysed and
incubated with an HA-DUB probe for 30 min.
Using anti-HA-coupled beads, we immunopre-
cipitated active DUBs were, and proteins were
separated on gel and analyzed by MS.
(B) Naı¨ve human CD4+ T cells were differentiated
to Th1, Th2, Th17, and Treg cells. mRNA expres-
sion of USP7 was analyzed by quantitative
RT-PCR. mRNA expression was normalized for
the housekeeping gene GAPDH.
(C) Ubiquitin pull-down for HA-Foxp3 or HA-Foxp3
K22xR as described in the Experimental Pro-
cedures.
(D) Cell lysates of HA-Foxp3- and Myc-USP7-
transfected cells were immunoprecipitated with
anti-HA- or anti-Myc-coupled beads. Immuno-
blots were analyzed with anti-HA or anti-Myc.
(E) Representative confocal microscopy images
of human Treg cells. Endogenous USP7 (red) and
Foxp3 (green) were visualized with specific anti-
bodies, and DAPI was used to visualize the nuclei
(blue).
(F) Foxp3-USP7 association was visualized in
human Treg cells with an in situ proximity ligation
assay as described in the Experimental Pro-
cedures. Punctate staining (green) indicates a
Foxp3-USP7 interaction as detected by the assay,
andDAPIwasused tovisualize thenuclei (blue). *p<
0.05. IP, immunoprecipitation; WB, western blot.
Data are represented as mean + SEM. See also
Figures S3 and S4.
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analyzed by MS. MS analysis identified the most intense protein
band as USP7 (coverage 26%), indicating that this DUB is active
in Treg cells (Figures 4A and S3A). Flow cytometric analysis of
CD4+CD25highFoxp3+ Treg cells confirmed that USP7 is ex-
pressed in Treg cells (Figure S3B). Given that Foxp3 expression
is critical during Treg cell development, we analyzed USP7
expression in iTreg cells. Naı¨ve cells were skewed to four
different Th cell subsets (Th1, Th2, Th17, and Treg cells; Fig-
ure S3C), and USP7mRNAwas analyzed by quantitative RTPCR
(qRT-PCR). USP7 mRNA expression was significantly upregu-
lated in iTreg cells but not in other Th subsets, further supporting
a role for the USP7 deubiquitination of Foxp3 in Treg cell differ-
entiation (Figure 4B). To determine whether USP7 could also
deubiquitinate Foxp3, we analyzed Foxp3 polyubiquitination in264 Immunity 39, 259–271, August 22, 2013 ª2013 Elsevier Inc.transfected HEK 293T cells. Foxp3 poly-
ubiquitination was reduced with ectopic
expression of USP7, indicating that
USP7 can directly deubiquitinate Foxp3
(Figure 4C). To validate that Foxp3 is
a direct USP7 substrate, we analyzed
the association of the two proteins
by coimmunoprecipitation in HEK 293T
cells (Figure 4D). A clear association
was observed, indicating that Foxp3 can
associate with USP7. To confirm that
both proteins interact in human Treg
cells, we fixed and permeabilized cells,and both endogenous Foxp3 and USP7 were visualized with
specific antibodies. The colocalization of both proteins was
observed in the nucleus (Figures 4E and S4A). Similar results
were obtained in cells ectopically expressing GFP-tagged
USP7 and mKate-tagged Foxp3 (Figure S4B). To further
confirm that ectopically expressed or endogenous USP7 and
Foxp3 can also directly associate in human Treg cells, we
performed an in situ proximity ligation assay (PLA; see the
Experimental Procedures). Given that a PLA signal can only be
obtained when the proteins of interest are in extremely close
proximity, this technique enables the detection of protein-pro-
tein interactions in cells. The association of USP7 and Foxp3
was observed, and the interaction was localized specifically to
the nucleus (Figures 4F and S4C). Taken together, these data
show that USP7, a DUB localized in the nucleus and interacting
Figure 5. USP7 Deubiquitinates Foxp3 in
Treg Cells
(A) HEK 293T cells were transfected with HA-
Foxp3 or HA-Foxp3 K22xR and Myc-USP7. Cell
lysates were quantified and analyzed by western
blotting with anti-HA and anti-HSP90.
(B) Cells were cotransfected with HA-Foxp3 and
Myc-USP7, Myc-USP14, or FLAG-UCHL3. Cell
lysates were analyzed for Foxp3 expression by
western blotting with anti-HA.
(C) Ubiquitin pull-down for HA-Foxp3 or HA-Foxp3
K22xR as described in the Experimental Pro-
cedures.
(D) Cells were transfected with USP7 siRNA along
with HA-Foxp3. Equalized protein lysates were
immunoblotted and analyzed for HA.
(E) USP7 was knocked down in human Treg cells
with shRNA lentivirus containing a puromycin
resistance cassette. Endogenous USP7 and
Foxp3 expression of puromycin-resistant Treg
cells were analyzed by flow cytometry.
(F) Primary Treg cells were isolated from Foxp3-
Ires-GFP mice and activated with anti-CD3
(5 mg/ml) and anti-CD28 (2 mg/ml) in the presence
of 100 U/ml IL-2 for 24 hr followed by either heat
shock treatment for 30min at 42Cor replacement
of fresh media with either LPS (1 mg/ml) or IL-6
(20 ng/ml) and cultured for an additional 24 hr
before being harvested for the western blots and
probed with the indicated antibodies.
(G) Primary Treg cells were isolated from Foxp3-
Ires-GFP mice and treated for 1 hr with IL-6
(50 ng/ml). Foxp3-USP7 association was visual-
ized with an in situ proximity ligation assay.
Punctate staining (green) indicates a Foxp3-USP7
interaction as detected by the assay, and DAPI
was used to visualize the nuclei (blue). All results
are representative for at least three independent
experiments. SC, scrambled; SP, smart pool; IP,
immunoprecipitation; WB, western blot.
See also Figure S5.
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biquitinate Foxp3.
USP7-Mediated Foxp3 Deubiquitination Results
in Increased Foxp3 Protein Expression
To determine whether USP7-mediated deubiquitination results
in increased Foxp3 protein amounts, we assessed Foxp3
expression in HEK 293T cells that were cotransfected with
Foxp3 and USP7. Ectopic expression of USP7 with Foxp3
noticeably increased Foxp3 protein amounts (Figure 5A).
Foxp3 K22xR protein amounts were not increased by the
cotransfection of USP7, indicating that USP7 stabilizes Foxp3
expression by direct deubiquitination. To verify these data, we
treated HEK 293T cells transfected with Foxp3 and USP7 with
CHX in order to determine the effect of USP7 on Foxp3 half-
life. Indeed, USP7 decreased the rate of degradation of Foxp3Immunity 39, 259–271(Figure S5A). Furthermore, a pulse chase
experiment was performed to determine
the half-life of Foxp3 or Foxp3 K22xR in
the presence or absence of USP7 (Fig-ure S5B). We observed a Foxp3 half-life of approximately 4 hr;
however, Foxp3 protein amounts were very stable in the pres-
ence of ectopically expressed USP7 or when all lysines were
mutated to arginines. Accordingly, Foxp3 half-life was similar
in a Foxp3-expressing Jurkat T cell line after treatment with
CHX, whereas Foxp3 K22xR was very stable (Figure S5C). To
investigate whether these observations were specific for USP7,
we analyzed the effect of additional DUBs. Using a global DUB
probe analysis, we found that both USP14 and UCH-L3 were
active in Treg cells (data not shown). In contrast to USP7, neither
USP14 nor UCH-L3 influenced Foxp3 protein expression or
Foxp3 polyubiquitination (Figures 5B and 5C). In addition, a
USP7 knockdown was performed in cells ectopically expressing
Foxp3 with a pool of four separate small interfering RNAs
(siRNAs; Figure S5D). USP7 knockdown resulted in markedly
reduced Foxp3 protein expression in comparison to control, August 22, 2013 ª2013 Elsevier Inc. 265
(legend on next page)
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Foxp3 Stabilization by USP7(Figure 5D). To verify these data in primary human Treg cells, we
performed USP7 knockdown with a USP7 small hairpin RNA
(shRNA) lentivirus containing a puromycin resistance cassette.
Foxp3 protein expression of puromycin-resistant Treg cells
was clearly decreased as a result of USP7 knockdown (Figures
5E and S5E). Accordingly, the protein expression of CD25, a
Foxp3 transcriptional target, was also reduced after USP7
knockdown (Figure S5F). Importantly, CD25 expression was un-
affected when USP7 was knocked down in Foxp3 Teff cells
(Figure S5G), providing support that the effect of USP7 on
CD25 expression is mediated through Foxp3. To further validate
that USP7 directly reduced Foxp3 protein expression because of
enhanced degradation and not indirectly through additional
mechanisms, we analyzed the activation status of multiple
signaling pathways in the presence or absence of USP7. No sig-
nificant differences in the downstream targets of TCR and TGF-b
signaling (phospho-ERK, phospho-SMAD3, or phospho-NFkB)
were observed between control andUSP7 knockdown Treg cells
(Figure S5H).
Foxp3 is acetylated at lysines 31, 249, 251, 263, and 267 (Kwon
et al., 2012; Song et al., 2012). Because we have previously
reported that acetylation can stabilize Foxp3 by preventing
ubiquitination, we wished to determine whether the expression
of the described mutants could still be influenced by USP7 (van
Loosdregt et al., 2010). HEK 293T cells were transfected with
Foxp3 K3R (lysines 31, 263, and 267), K4R (lysines 249, 251,
263, and 267), or K5R (lysines 249, 251, 263, 267, and 393) in
the presence or absence of USP7, and Foxp3 expression was
determined. Cotransfection of USP7 increased the expression
of all the mutants, demonstrating that the expression of these
specific mutants can still be regulated by USP7 (Figure S5I).
Next, we sought to determine which signals could regulate
USP7 expression and, thus, Foxp3 stability. Primary Treg cells
from Foxp3-GFP mice were activated and stimulated with lipo-
polysaccharide (LPS), heat shock, or IL-6 and cultured for
24 hr. USP7 expression was reduced by these treatments,
and, accordingly, Foxp3 protein expression was also reduced
in these samples (Figure 5F). To analyze whether IL-6 could
also disrupt association of Foxp3 and USP7, we treated freshly
isolated Foxp3-GFP Treg cells with IL-6 for 1 hr, and a PLA
was performed. As depicted in Figure 5G, short-term IL-6 treat-
ment disrupted the association between Foxp3 and USP7.
Taken together, these data demonstrate that USP7 activity in
Treg cells stabilizes Foxp3, a process that can be disrupted by
inflammatory stimuli.Figure 6. USP7 Modulates Treg Cell Function In Vitro and In Vivo
(A) IL-2 promoter luciferase activity was analyzed in HEK 293T cells by cotrans
reporter activity is depicted, and all values were normalized for cotransfected Re
(B) USP7 knockdown in human Treg cells was performedwith two different USP7 s
control. Analysis of Treg-cell-mediated suppression was performed with a stand
(C) Colitis was induced by intravenous coinjection of 13 106 CD4+CD25CD62Lh
body weight over time were expressed as a percentage of the original weight. D
(D) Histological examination of the colon at 8 weeks after cell transfer.
(E) Histological scores were determined at 8 weeks after cell transfer as describ
(F) Spleen, mesenteric lymph node and lamina propria lymph node cells were isol
Teff cells was determined by flow cytometry.
(G) Cell numbers of injected Thy1.1+ Treg cells and Foxp3+ cells were determine
(H) IFN-g and IL-17 production by CD4+ lamina propria lymphocytes was analys
See also Figure S6.USP7-Mediated Foxp3 Deubiquitination Improves Treg
Cell Functionality
Given that we observed a clear effect of USP7 on Foxp3 protein
stability, we subsequently analyzed the effect of USP7 on Foxp3
transcriptional activity. Promoter activity of the canonical Foxp3
transcriptional target IL2 was evaluated with an IL2 promoter
luciferase reporter. Foxp3 expression resulted in a clear repres-
sion of IL2 promoter activity, whereas the well-characterized
IPEX mutant Foxp3 Del250 was inactive (Figure 6A). Although
cotransfection of Foxp3 Del250 with USP7 alone did not influ-
ence IL2 reporter activity, USP7 significantly increased IL2
promoter repression mediated by WT Foxp3. To determine
whether USP7 can specifically modulate Treg-cell-mediated
suppression, we performed a USP7 knockdown with two
distinct shRNAs, and Treg cell functionality was addressed
with an in vitro suppression assay (Figures 6B and S6A). Both
USP7 shRNAs significantly abrogated Treg-cell-mediated sup-
pression in comparison to the scrambled shRNA control without
affecting apoptosis (Figure S6B). Accordingly, IL-2 expression
was also increased in Treg cells upon USP7 knockdown
(Figure S6C).
To determine whether USP7 activity could also modulate
Treg-cell-mediated suppression in vivo, we once again used a
mouse colitis model. Here, naı¨ve CD4+CD25CD62Lhigh T cells
were cotransferred with CD4+CD25high USP7 knockdown Treg
cells into Rag2/ mice. In contrast to WT or control knockdown
Treg cells, USP7 knockdown Treg cells could not suppress the
development of disease based on both body weight loss and
histological analysis of the colon (Figures 6C, 6D, and 6E). Equiv-
alently, Teff cell numbers in the spleen, mesenteric, and lamina
propria lymph nodes were increased in mice that received
shUSP7 Treg cells in comparison to controls (Figure 6F). In addi-
tion, the numbers of Thy1.1 Treg cells were similar in both the
control and USP7 knockdown group, demonstrating that USP7
knockdown did not alter Treg cell survival or homing to lymph
nodes (Figures 6G and S6D). Importantly, the percentage of
Foxp3+ cells within the Thy1.1 population was decreased in
mice that received USP7 knockdown Treg cells, indicating that
knockdown of USP7 resulted in decreased Foxp3 expression,
which was in line with our in vitro observations. Accordingly,
IFN-g and IL-17 production by CD4+ lamina propria lymphocytes
was increased in mice that received USP7 knockdown Treg cells
(Figure 6H). Collectively, these data demonstrate that USP7
can regulate Treg-cell-mediated suppression both in vitro and
in vivo.fecting NFAT with Foxp3 Del250 or WT Foxp3 with USP7. Repression of IL2
nilla.
hRNAs (#1 or #2), and scrambled (SC) shRNAwas used as control was used as
ard suppression assay.
igh T cells and 23 105 CD4+CD25high Treg cells per Rag2/mouse. Changes in
ata are represented as the mean + SEM of eight mice in each group.
ed in the Experimental Procedures.
ated from the mice at 8 weeks after adoptive T cell transfer, and the number of
d by flow cytometry.
ed by ELISA. Data are represented as mean + SEM. *p < 0.05.
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The transcription factor Foxp3 is crucial for Treg cell develop-
ment and function and, therefore, is critical in controlling immune
responses (Khattri et al., 2003; Fontenot et al., 2003; Hori et al.,
2003; Williams and Rudensky, 2007). Because Foxp3 protein
expression is directly associated with the suppressive capacity
of Treg cells, many studies have focused on the transcriptional
regulation of Foxp3 expression (Wan and Flavell, 2007; Kim
and Leonard, 2007; Tone et al., 2008). Here, we show that
Foxp3 protein expression can also be regulated by the deubiqui-
tinase USP7. USP7 expression was found to be upregulated in
Treg cells and to interact with and deubiquitinate Foxp3, thereby
increasing Foxp3 protein amounts. USP7 knockdown in Treg
cells resulted in decreased Foxp3 protein expression and
impaired Treg-cell-mediated suppression both in vitro and
in vivo. These data provide insights into the molecular mecha-
nisms regulating Foxp3 protein expression and, therefore, Treg
cell functionality.
We also demonstrate that stimulation with IL-6, heat shock,
or LPS reduces USP7 protein amounts and, thus, Foxp3
expression. Our data are in accordance with a recent study
by Yang et al. (2012) that reports that, in colon tumors, IL-6
can inhibit USP7 expression in a STAT3-dependent manner.
Furthermore, we show that the association of USP7 and
Foxp3 is disrupted upon short-term IL-6 stimulation. These
data indicate that the effects of IL-6 stimulation on Foxp3
protein expression can be both rapid through the disruption
of USP7-Foxp3 association and prolonged by the reduction
of USP7 expression.
Although it was initially thought that Foxp3 expression was
unique for Treg cells, several studies have reported that Foxp3
can also be expressed in activated T cells. The stimulation of
human CD4 cells in vitro with anti-CD3 and anti-CD28 or phorbol
12-meristate 13-acetate and Ca2+ ionophore resulted in the tran-
sient expression of Foxp3, although protein amounts were lower
in comparison to nTreg cells (Gavin et al., 2006; Allan et al.,
2005). Analysis of these T cells transiently expressing Foxp3
revealed that these cells cannot suppress cytokine production
or proliferation of cocultured T cells (Gavin et al., 2006; Allan
et al., 2005). In contrast, TCR-stimulated CD4+CD25 cells ex-
pressing high and stable Foxp3 amounts develop suppressive
capacity, whereas the ablation of Foxp3 in mature Treg cells in
mice with a loxP-flanked Foxp3 allele resulted in a loss of
Treg-cell-mediated suppression and the production of IL-2 and
Th1 cytokines (Williams and Rudensky, 2007; Wang et al.,
2007; Gavin et al., 2006). Here, we demonstrate that the turnover
of Foxp3 in primary Treg cells is relatively high. Given that Foxp3
transcription rates are normally equal to its degradation rates,
the total pool of Foxp3 protein is stable. This high turnover allows
for a rapid regulation of Foxp3 protein expression by the modu-
lation of Foxp3 polyubiquitination and degradation. These data
demonstrate that stable Foxp3 expression is a necessity for
the suppressive phenotype of Treg cells, suggesting that the
stabilization of Foxp3 by USP7 may provide an essential step
in the conversion of activated T cells into iTreg cells. In agree-
ment with this hypothesis, we observed a more than 10-fold
increase of USP7 mRNA in Treg cells induced from a naı¨ve
T cell pool in comparison to other Th subsets.268 Immunity 39, 259–271, August 22, 2013 ª2013 Elsevier Inc.Using MS, we identified five distinct lysine residues that were
ubiquitinated (K249, K251, K263, K267, and K393). Although a
mutant of Foxp3 lacking all lysine residues (Foxp3 K22xR)
was not ubiquitinated, the addition of the five identified lysines
in the Foxp3 K22xR background restored Foxp3 ubiquitination.
The addition of K249, K251 and K393, or K263 and K267 was
also sufficient to restore Foxp3 ubiquitination to WT levels,
suggesting a level of promiscuity in which lysine residues are
ubiquitinated. Furthermore, generating an N-terminal ubiquitin-
Foxp3 fusion protein dramatically increased Foxp3 poly-
ubiquitination, demonstrating that the specific location of
Foxp3 polyubiquitinated lysine residues is apparently not crit-
ical. The promiscuity of ubiquitinated lysine residues is a
commonly observed phenomenon and has been described for
a variety of proteins (Lee et al., 2004; Lu et al., 2007; Huang
et al., 2006). For example, with the use of MS, the DUB UCH-
L1 was also found to be ubiquitinated on at least four lysine res-
idues (Meray and Lansbury, 2007). The mutation of all four lysine
residues did not result in reduced ubiquitination levels, only a
UCH-L1 protein in which all 16 lysine residues were mutated
showed severely reduced ubiquitination levels. In addition, the
mutation of single ubiquitinated lysine residues may result in
ubiquitination of secondary lysine residues that are not normally
ubiquitinated, as has been observed in TCRx chain and Gpa1
(Hou et al., 1994; Marotti et al., 2002). This promiscuity poten-
tially allows the possibility for multiple mechanisms to regulate
Foxp3 protein expression.
Interestingly, USP7 polymorphisms have been associated
with multiple autoimmune diseases. In a genome-wide associa-
tion study, 14,000 cases of seven common diseases were
compared to 3,000 controls (Wellcome Trust Case Control
Consortium, 2007). Numerous single-nucleotide polymorphisms
in the USP7 gene were highly significantly correlated with
the autoimmune diseases, including Crohn’s disease, insulin-
dependent diabetes mellitus, and rheumatoid arthritis. The pre-
cise effect of these polymorphisms on USP7 function remains
unclear. Because we demonstrate that USP7 increases Treg-
cell-mediated suppression in multiple models, it is tempting to
speculate that these USP7 polymorphisms may inhibit USP7
function, resulting in reduced Foxp3 expression, abrogating
Treg cell functionality, and, thus, leading to autoimmunity.
Treg cells are found in increased numbers both within and in
close proximity to solid tumors. They have been shown to inhibit
tumor-specific T cell immunity and contribute to the growth of
human tumors in vivo (Yang et al., 2006; Curiel et al., 2004).
The depletion of CD4+CD25+ cells in vivo augments the genera-
tion of tumor-specific T cells and promotes the rejection of
tumors derived from myeloma, sarcoma, and melanoma (Turk
et al., 2004; Onizuka et al., 1999). These data suggest that the
inhibition of Treg cell numbers and function could also provide
a potent antitumor therapy. Compounds inhibiting USP7 could
potentially be clinically relevant when used to treat diseases,
given that we have demonstrated that the inhibition of USP7
results in decreased Foxp3 protein expression, preventing
Treg-cell-mediated suppression.
We propose a molecular mechanism regulating the effi-
ciency of Treg-cell-mediated immune modulation. We demon-
strate that Foxp3 protein expression can be tightly regulated
by polyubiquitination-mediated proteosomal degradation. The
Immunity
Foxp3 Stabilization by USP7modulation of USP7 activity may provide a novel molecular
therapy aimed to control (inappropriate) immune responses.
EXPERIMENTAL PROCEDURES
Antibodies, DNA Constructs, and Reagents
The following antibodies were used: mouse anti-Foxp3 clone PCH101 for fluo-
rescence-activated cell sorting analysis (eBioscience), mouse anti-FLAG M2
from Sigma-Aldrich, mouse anti-HA clone 12CA5 from Santa Cruz Biotech-
nology, and mouse anti-tubulin (Sigma-Aldrich), and anti-Myc monoclonal Ab
were made with a hybridoma cell line. Foxp3 was cloned from MIGR1-Foxp3
(which was kindly provided by S. Sakaguchi) (Hori et al., 2003) into pMT2 con-
taining a HA-tag-generating pMT2-HA-Foxp3. pMT2-FLAG-Foxp3, pMT2-
FLAG-Foxp3DE250, and pRSV-NFATC/A have been described previously
(van Loosdregt et al., 2013). HA-Ubi and HA-UbiK7xR were described previ-
ously (van der Horst et al., 2006). Foxp3 lysine mutants were obtained by
site-directed mutagenesis. Myc-USP7 has been described previously (Meul-
meester et al., 2005). pcDNA3, CHX, and MG132 were purchased from
Sigma-Aldrich. The HA-DUB probe and DUB inhibitor have been described
previously (Borodovsky et al., 2002; Colombo et al., 2010; Patent WO, 2007).
Luciferase Assays
Luciferase reporter assays were performed as previously described (van Loos-
dregt et al., 2011).
Confocal Imaging
Localization Studies
Localization experiments were performed as previously described (van Loos-
dregt et al., 2010).
Proximity Ligation Assay
PLA detection was performed with a Duolink II kit (Olink Bioscience) as previ-
ously described (van Loosdregt et al., 2011).
Pulse Chase Analysis
Transfected HEK 293T cells were washed and depleted from methionine and
cysteine for 30min in depletion medium (Dulbecco’s modified Eagle’s medium
[DMEM] without Met and Cys, Invitrogen), pulsed for 17 min with depletion
medium containing 35S Met + Cys (100 mCi/ml, PerkinElmer), washed, and
subsequently chased in chase medium (DMEM with Met and Cys + 100 ſM
methionine). Cells were washed in stop buffer (PBS + 100 mM N-ethylmalei-
mide) and lysed in lysis buffer (1% Triton, 1 mM EDTA, and Halt Protease
Inhibitor Cocktail [1:100] in PBS). Lysates were incubated with Anti-FLAG
M2 Affinity Gel-coupled beads (Sigma-Aldrich) for 2 hr at 4C. Beads were
washed three times, boiled once in sample buffer, and subjected to gel
electrophoresis. Radioactive labeled FLAG-Foxp3 was analysed with phos-
phorscreen and a Storm 860 phosphorimager (GE Healthcare).
TUBEs Ubiquitination Assay
Ubiqutination of endogenously expressed protein was determined with
Agarose-TUBE 2 according to the manufacturer’s protocol (LifeSensors).
Isolation of Active DUBs with the HA-DUB Probe
HA immunoprecipitation of the HA-DUB probe was performed as described
previously (Borodovsky et al., 2002).
Immunoprecipitation
Immunoprecipitation experiments were performed as described previously
(van Loosdregt et al., 2010).
In Vitro Suppression Assay
Human CD4+CD25highCD127low Treg cells (top 2%) were sorted and cocul-
tured with CFSE-labeled PBMCs (1:5 ratio) in anti-CD3 (clone OKT3)-coated
96-well plates. Cells were cultured for 4 days in RPMI medium supplemented
with 10% fetal calf serum (FCS), 100 units/ml penicillin, 100 mg/ml strepto-
mycin, and 5 3 10–5 M 2-mercaptoethanol. Proliferation of CD4+ and CD8+
was determined by measuring CFSE dilution with a FACSCANTO flow cytom-
eter (BD Biosciences).Generation of iTreg Cells
CD4+CD25 cells were isolated from cord blood by magnetic-activated cell
sorting and cultured in RPMI 1640 supplemented 10%FCS, 100 units/ml peni-
cillin, 100 mg/ml streptomycin, and 5 3 10–5 M 2-mercaptoethanol. Foxp3
expression was induced by culturing the cells for 5 days in combination with
anti-CD3 anti-CD28 Dynabeads, 300 IU IL-2, and 10 nM TGF-b.
Ubiquitin Pull-Down Assay
Cells transfected with both His-tagged ubiquitin and HA-tagged Foxp3 were
treated with 20 mM MG132 and 10 mM DUBi for 3 hr. Cells were lysed in a
pH 8 urea buffer (8 M urea, 100 mM Na2HPO4, 10 mM TRIS [pH 8.0], 0.2%
TX-100, 10 mM imidazole, and 1 mM N-ethylmaleimide) and tumbled with
Ni-NTA beads for 2 hr at room temperature. The beads were washed twice
in pH 8 urea buffer, twice in pH 6.3 urea buffer (8 M urea, 100 mM Na2HPO4,
10 mM TRIS [pH 6.3], 0.2% TX-100, and 10 mM imidazole), and once in a
wash buffer (20 mM TRIS [pH 8.0], 100 mM NaCl, 20% glycerol, 1 mM dithio-
threitol, and 10 mM imidazole). Beads were boiled in sample buffer for 5 min
and separated on SDS-PAGE, and Foxp3-specific polyubiquitination was
determined by western blot analysis with anti-HA.
T Cell Differentiation
We cultured 100,000 sorted CD4+CD27+CD45RO naı¨ve T cells derived from
human PBMCs in 96-well plates coated with 0.3 mg/ml anti-CD3 and 2 mg/ml
soluble anti-CD28 for 4 days. For skewing towards different T cells subsets,
the cultures were supplemented with the following cytokines and antibodies:
Th1, IL-12 (200 U/ml) + anti-iL-4 (10 mg/ml); Th2, IL-4 (1000 U/ml) + anti-
iFNg (5 mg/ml); Th17, TGFb (10 ng/ml) + IL-6 (20 ng/ml) + IL1b (10 ng/ml) +
IL-23 (100 ng/ml); Treg, IL-2 (300 U/ml) + TGFb (10 ng/ml).
Induced Colitis Mouse Model for DUBi-Treated Treg Cells
Rag1/ mice were kept in the animal facility of the Utrecht University under
specific pathogen-free conditions. The experiments were approved by the
Animal Experiment Committee of the Faculty of Veterinary Medicine (Utrecht
University). Immunodeficient Rag1/ mice were injected with 4 3 105
CD4+CD45RBhigh cells in order to induce colitis. After 21 days, 2 3 105 Treg
cells isolated from Foxp3-GFP mice were pretreated with 10 mM DUBi for
1 hr, washed, and intravenously injected. The mice were sacrificed 3 weeks
later, and tissue slides of the colon were prepared. Scoring was performed
as described previously (Zaiss et al., 2013).
Induced Colitis Mouse Model for USP7 KD Treg Cells
Naı¨ve CD4+CD25CD62Lhigh T cells were isolated from BALB/c and intrave-
nously injected into BALB/c Rag2/ immunodeficient recipients (1 3 106
per mouse). CD4+CD25+ Treg cells or siRL- or siUSP7-transduced Treg cells
(2 3 105) isolated from Thy1.1 BALB/c were intravenously coinjected where
indicated. After 8 weeks, mice were sacrificed, and tissue slides of the colon
were prepared and scored as described.
Statistical Analysis
Statistical analysis was performed with the Mann-Whitney test (GraphPad
Prism). p < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information contains six figures and can be found with this
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